BC 11-38

CAS No. 686770-80-9

BC 11-38( —— )

Catalog No. M27479 CAS No. 686770-80-9

BC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 70 In Stock
5MG 61 In Stock
10MG 93 In Stock
25MG 202 In Stock
50MG 323 In Stock
100MG 516 In Stock
200MG 732 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BC 11-38
  • Note
    Research use only, not for human use.
  • Brief Description
    BC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM).
  • Description
    BC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM). (In Vitro):BC 11-38 ignificantly elevates cAMP levels and cortisol production in H295R human adenocarcinoma cells .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    686770-80-9
  • Formula Weight
    304.43
  • Molecular Formula
    C15H16N2OS2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (109.48 mM)
  • SMILES
    O=C1C2=C(CCS2)N=C(SCCC)N1C3=CC=CC=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.J Zhang , et al. Effect of steroidal saponins of Anemarrhenae rhizoma on superoxide generation in human neutrophils. Biochem Biophys Res Commun. 1999 Jun 16;259(3):636-9.
molnova catalog
related products
  • GSK-256066

    A potent, selective PDE4 inhibitor with pIC50 of 11.5, 11.3, 11.4, and 11.9 for PDE4B, A, C, and D, respectively.

  • LJI308

    LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.

  • Mirodenafil

    Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.The pharmacoki-netics of mirodenafil were not significantly altered by this concurrent administration. Mirodenafil (50 or 100 mg), obviously improved erectile function and was well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.